GSE76425 lenalidomide 1 v 10 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE76425_lenalidomide_1_v_10_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE76425_lenalidomide_1_v_10_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE76425_lenalidomide_1_v_10_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE76425_lenalidomide_1_v_10_human_up.

Results found

Linked to

 

Label

Description

 

Gene

colony stimulating factor 2 receptor subunit alpha

Gene

Pvt1 oncogene

Gene

lung cancer associated transcript 1

Gene

myocardial infarction associated transcript

Gene

long intergenic non-protein coding RNA 1133

Gene

LHFPL3 antisense RNA 2

Gene

colorectal cancer associated 1

Gene

RNA component of 7SK nuclear ribonucleoprotein

Gene

SH3BP5 antisense RNA 1

Gene

uncharacterized LOC100192386

  • Gene

    colony stimulating factor 2 receptor subunit alpha



  • Gene

    lung cancer associated transcript 1


  • Gene

    myocardial infarction associated transcript


  • Gene

    long intergenic non-protein coding RNA 1133


  • Gene

    LHFPL3 antisense RNA 2


  • Gene

    colorectal cancer associated 1


  • Gene

    RNA component of 7SK nuclear ribonucleoprotein


  • Gene

    SH3BP5 antisense RNA 1


  • Gene

    uncharacterized LOC100192386

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.